Gerd & Nerd Treatment Market Research Report – Americas Forecast Till 2023


Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid And Liquid), End User (Hospitals & Clinics, Research Centers, And Others) – Americas Forecast Till 2023

SKU: 190511 Category:


Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid and Liquid), End User (Hospitals & Clinics, Research Centers, And Others) – Americas Forecast Till 2023
Market Analysis
In the course of the last two hundred years, indigestion has been one of the common health issues in the U.S. However, a definitive objective of the gastroesophageal reflux treatment has dependably continued as before, which is to stifle the side effects of the GERD patient. GERD influences up to 40% of the U.S. populace in their lifetime and currently, most of the people are facing this health condition. If the GERD isn’t appropriately overseen, it can prompt Barrett’s esophagus. Early treatment of Barrett’s esophagus is significant in light of the fact that it is the essential risk factor for esophageal cancer. The frequency of indigestion issue, otherwise called acid reflux, is quickly expanding around the world. According to various studies almost each individual experiences acid reflux at least once in their lifetime. GERD is one of the regularly watched intermittent gastrointestinal disorders around the world. The Americas GERD & NERD treatment market is anticipated to grow at the CAGR of 4.02% during the forecast period 2017-2023.
This issue not just affects the health and nature of patient lives yet, in addition, stretches out to the healthcare economy and system. The real driving elements for the development of the market are expanding instances of smoking, rising instances of reflux issue amid pregnancy, evolving way of life, and sporadic dietary propensities. In addition, expanding occurrence of indigestion issue (acid reflux), developing geriatric populace is probably going to fuel the market development.
Market Segmentation
The Americas GERD & NERD treatment market is classified on the basis of its drug class, end user, dosage form, and regional analysis. Based on its drug class, the market is bifurcated into proton pump inhibitors, antacids (acid neutralizers), H2 receptor blocker, antidepressants, prokinetic agents, calcium channel blockers, among others. On the basis of its dosage form, the Americas GERD & NERD treatment market is divided into liquid and solid. Based on its end-user industry, the global market is segmented into research centers, hospitals & clinics, and others.
Regional Analysis
Geographically, the Americas GERD & NERD treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Industry Players
The list of major players in the Americas GERD & NERD treatment market include companies like AstraZeneca Plc (U.K), Cempra Inc. (U.S.), Boston Scientific Corporation (U.S.), Eisai Co., Ltd. (Japan), EndoStim Inc. (U.S.), EndoGastric Solutions Inc. (U.S.), GlaxoSmithKline Plc (U.K), Jeil Pharmaceutical Co. Ltd. (South Korea), Ironwood Pharmaceuticals, Inc. (U.S.), Johnson & Johnson (U.S.), Medigus Ltd. (Israel), Mederi Therapeutics Inc. (U.S.), Medtronic Inc. (U.S.), Valeant Pharmaceuticals International, Inc. (Canada), Allegiant health (U.S.), Tya pharmaceuticals (U.S.), among others.

Table of Contents

Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Data Points Received from the Doctors/ Gastrologist:
3.1.3 Data points received from the Manufacturer/ Pharmaceutical Companies:
3.1.4 Data points received from Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing cases of smoking to boost the market growth (Impact weightage- 20%)
4.2.2 Rising cases of reflux disorder during pregnancy (impact weightage- 15%)
4.2.3 Changing lifestyle and irregular dietary habits (Impact weightage- 15%)
4.2.4 Increasing incidence of acid reflux disorder (heartburn) will boost the American GERD& NERD treatment market (Impact weightage- 25%)
4.2.5 Growing geriatric population (impact weightage- 15%)
4.2.6 Increasing demands for endoscopy biopsy procedures for early diagnosis (Impact weightage- 10%)
4.3 Restraints
4.3.1 Loss of patent exclusivity and lack of pipeline drugs (impact weightage- 55%)
4.3.2 High cost of the gastroscopes (weightage impact- 45%)
4.4 Opportunity
4.4.1 Development of new drugs
4.5 Mega Trends
4.6 Macroeconomic Indicators
4.7 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Porters Five forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Americas GERD & NERD Treatment Market, by Drug class
6.1 Introduction
6.2 Antacids (Acid Neutralizers)
6.3 Proton Pump Inhibitors
6.3.1 Esomeprazole
6.3.2 Omeprazole
6.3.3 Pantoprazole
6.3.4 Lansoprazole
6.3.5 Dexlansoprazole
6.3.6 Rabeprazole
6.4 H2 receptor blocker
6.4.1 Ranitidine
6.4.2 Famotidine
6.4.3 Cimetidine
6.4.4 Nizatidine
6.5 Pro kinetic agents
6.5.1 Domperidone
6.5.2 Metoclopramide
6.5.3 Itopride
6.5.4 Prucalopride
6.5.5 Cisapride
6.5.6 Benzamide
6.5.7 Mosapride
6.5.8 Erythromycin
6.6 Antidepressants
6.7 Calcium Channel Blockers
7 Americas GERD & NERD Treatment Market, by Dosage Form
7.1 Introduction
7.2 Solid
7.3 Liquid
8 Americas GERD & NERD Treatment Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Research Centers
9 Americas GERD & NERD Treatment Market, by Region
10 Americas GERD & NERD Treatment Market, by Region
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 South America
11 Competitive Landscape
11.1 Introduction
11.2 Company Share Analysis
12 Company Profiles
12.1 AstraZeneca
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Products
12.1.4 Strategy
12.1.5 Key Developments
12.2 Addex Pharmaceuticals
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Products
12.2.4 Strategy
12.2.5 Key Developments
12.3 Takeda Pharmaceutical
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Products
12.3.4 Strategy
12.3.5 Key Developments
12.4 Eisai Co., Ltd
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Products
12.4.4 Strategy
12.4.5 Key Developments
12.5 Medigus Ltd
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Products
12.5.4 Strategy
12.5.5 Key Developments
12.6 RaQualia Pharma Inc
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Products
12.6.4 Strategy
12.6.5 Key Developments
12.7 Torax Medical
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Products
12.7.4 Strategy
12.7.5 Key Developments
12.8 Carbon Medical technologies
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Products
12.8.4 Strategy
12.8.5 Key Developments
12.9 Endogastric Solutions
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Products
12.9.4 Strategy
12.9.5 Key Developments
12.1 Medtronic
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Products
12.10.4 Strategy
12.10.5 Key Developments
12.11 Pfizer
12.11.1 Company Overview
12.11.2 Financials
12.11.3 Products
12.11.4 Strategy
12.11.5 Key Developments
12.12 Novartis AG.
12.12.1 Company Overview
12.12.2 Financials
12.12.3 Products
12.12.4 Strategy
12.12.5 Key Developments
12.13 GlaxoSmithKline plc
12.13.1 Company Overview
12.13.2 Financials
12.13.3 Products
12.13.4 Strategy
12.13.5 Key Developments
12.14 Valeant Pharmaceuticals
12.14.1 Company Overview
12.14.2 Financials
12.14.3 Products
12.14.4 Strategy
12.14.5 Key Developments
12.15 Ironwood Pharmaceuticals, Inc.
12.15.1 Company Overview
12.15.2 Financials
12.15.3 Products
12.15.4 Strategy
12.15.5 Key Developments
13 Appendix
13.1 Discussion Blue Print
14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs
14.2 Key companies to watch

Additional information


Geography Covered

Date Published